Sitemap
Pages
- Leadsform
- ECP Florence September 2024 – Booking a meeting
- Booking Received
- Cost calculator
- Your inbox, your rules with OncoDNA!
- Cookie Policy (EU)
- Certifications & Accreditations
- Webinar: Advancing personalized cancer treatment: explore the synergy of Twist Bioscience & OncoDNA
- Home
- Twist Webinar
- Awards
- For Clinical Research
- For Oncology Professionals
- For Biotechs and Pharma professionals
- Team
- For Laboratory Professionals
- Careers
- Submit complaint
- Patients & Relatives
- Download OncoDEEP report
- Request a Demo
- Order Kit
- About OncoDNA Group
- Project Care
- Biological (Mercury™)
- Clinical and biological interpretation (OncoKDM)
- Our Blog & Resources
- Contact
Posts
Article
- Comprehensive Genomic Profiling of Solid Tumor Patients for Broad Analysis in clinical diagnostics – A Comparative Analysis of OncoDEEP® Kit and Illumina TSO500 - 5 May 2024
- DigiONE : A European digital research network for oncology - 18 April 2024
- OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing services - 23 February 2024
Case of the Month
- March: 42-year-old male with a metastatic colorectal cancer - 18 March 2024
- February: 40-year-old male with a stage IV glioma cancer - 20 February 2024
- January: 45-year-old male with an intrahepatic cholangiocarcinoma - 16 January 2024
- December: 52-year-old male with a stage IV gastric cancer - 19 December 2023
- November: 68 year-old man with a Stage IV Prostate cancer - 14 November 2023
- October: 65 year-old woman with a Metastatic Breast Cancer with hormone receptor (HR)-positive - 31 October 2023
- September: 53 year-old man with Metastatic Colorectal Cancer - 29 September 2023
- July: 53 year-old man with Non-Small Cell Lung Cancer - 24 July 2023
- HRD in Ovarian Cancer Treatment: 60 year-old woman with Metastatic Ovarian Cancer - 16 May 2023
Lab Case
- Enhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies - 29 September 2023
- Revolutionizing laboratory operations with OncoDEEP® Kit - 18 June 2023
Poster
- Analytical validation of HRD calculation performed with the OncoDEEP® Kit Comprehensive Genomic Panel - 25 June 2024
- Detection of Intraspecies Contamination as a Quality Control Tool in The OncoDEEP® Kit Comprehensive Genomic Panel - 24 June 2024
- Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer - 22 January 2024
- Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers - 8 January 2024
- Ultra-sensitive detection of MRD through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer - 12 December 2023
- ctDNA’s promise in early detection of MRD and recurrence prediction for Head and Neck Squamous Cell Carcinoma - 2 November 2023
- Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD) - 19 October 2023
Press Release
- Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument. - 28 February 2024
- Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine - 17 January 2024
- OncoDNA laboratory has received the CAP accreditation - 4 January 2024
- OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, Germany - 4 December 2023
- OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancer - 23 November 2023
- OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands - 7 November 2023
- OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house - 20 October 2023
- C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe - 19 October 2023
- OncoDNA announces the closing of a round C financing of 6,5 M€ - 3 July 2023
- Collaboration between OncoDNA and Eli Lilly Italia to broaden access to biomarker testing for thyroid cancer patients - 24 November 2022
- Berkshire and Surrey Pathology Services & OncoDNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK - 18 October 2022
- OncoDNA announces the operational launch of its OncoDEEP® Kit for comprehensive genomic profiling of solid tumors - 12 September 2022
- OncoDNA and Synlab partner to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany - 29 March 2022
- OncoDNA launches OncoDEEP® Kit for comprehensive biomarker testing of solid tumors - 10 February 2022
- C2i Genomics partners with OncoDNA to bring AI-powered liquid biopsy for cancer diagnostics across Europe - 10 January 2022
- OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology - 16 December 2021
- OncoDNA provides strategic support in Radiomics’ prospective clinical trial SALMON - 25 November 2021
- OncoDNA teams up with SOPHiA GENETICS to enable laboratories to establish data-driven medicine as a standard of care - 30 September 2021
- New partnership to advance identification of best treatments for cancer patients - 9 August 2021
- Collaboration between Bayer Saudi Arabia LLC, OncoDNA and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia - 13 July 2021
- Institut Jules Bordet collaborates with OncoDNA to explore biology of brain metastases using personalized liquid biopsy from cerebrospinal fluid - 17 June 2021
- OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers - 15 April 2021
- Fighting cancer with personalized vaccines: OncoDNA and myNEO join forces to unlock the power of mRNA therapeutics - 7 April 2021
- OncoDNA supports BSMO project to advance precision medicine for late stage cancer patients across Belgium - 4 February 2021
- OncoDNA appoints Dr Bernard Courtieu as Chief Executive Officer - 25 January 2021
- OncoDNA announces expansion of its services into the United States - 7 January 2021
- OncoDNA wins the Biotech Award of Deloitte’s 2020 Technology Fast50 competition - 27 November 2020
- New molecular diagnostic innovation partnership to facilitate patient access to personalised cancer care across the UK - 24 November 2020
- Successful friendly takeover bid initiated by OncoDNA on IntegraGen’shares - 17 November 2020
- OncoDNA has been nominated for the Deloitte’s 2020 Technology Fast 50 - 10 November 2020
- American Hospital of Paris and OncoDNA Partner to Advance Breast Cancer Patients Management - 13 October 2020
- OncoDNA signs collaboration agreement with the European Cancer Patient Coalition on the 2020 personalised medicine awareness project - 24 September 2020
- OncoKDM® used as the support SaaS platform in a prospective pilot study of Veneto Institute of Oncology – IRCCS - 10 September 2020
- OncoDNA has been nominated for the 2020 BVA Award Growth Company of the Year - 8 September 2020
- ONCODNA provides an update about the friendly takeover bid on INTEGRAGEN - 12 August 2020
- Agreement to file a friendly takeover bid initiated by OncoDNA on IntegraGen to acquire all outstanding shares at a price of 2.20€ per share - 9 July 2020
Scientific Application Note
- Cancer Management: Breast Cancer - 24 July 2023
- Comprehensive Ovarian Cancer Treatment and Management - 9 June 2023
- Advanced lung cancer treatment and diagnostic solutions - 15 May 2023
- ctDNA as predictive biomarker of everolimus efficacy in advanced luminal breast cancer - 4 October 2021
- OncoDNA supports the AURORA study to identify molecular changes driving metastatic breast cancer - 6 July 2021
- Analysis of prognostic and predictive factors of response in squamous cell carcinoma using comprehensive biomarker testing - 21 May 2021
- BRCA1/2 mutation detection in breast cancer tumor tissue using NGS and OncoKDM - 12 May 2021
- Study assesses the clinical activity of tipifarnib for HNSCC patients with HRAS mutations using OncoKDM - 21 April 2021
- The economics of comprehensive biomarker testing in cancer - 24 March 2021
- When is the optimal time for biomarker testing in the patient pathway? - 26 February 2021
- ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report - 23 February 2021
- Something old, something new: when is a new biopsy preferable for biomarker analysis? - 31 January 2021
- Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) - 21 January 2021
- The evolution of BRCA testing: treatment & prevention opportunities - 20 December 2020
- Biomarker testing and horizon scanning help plan future treatments for patients - 19 November 2020
- What’s on the horizon for immunotherapy? - 15 October 2020
- The current landscape of biomarker directed therapy in oncology - 16 September 2020
- COVID-19 Pandemic : Determinants of COVID-19 disease severity in patients with cancer - 20 August 2020
- COVID-19 Pandemic : Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis - 20 August 2020
- Lung Cancer : Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis - 20 August 2020
- Brain Tumours : MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas - 20 August 2020
- Immunotherapy : Escape from nonsense-mediated decay associates with anti-tumor immunogenicity - 20 August 2020
- The fluid landscape of liquid biopsy - 13 August 2020
- Endometrial Cancer Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002) - 11 August 2020
- Biliary Tract Cancer Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial - 11 August 2020
- BREAST CANCER Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer - 11 August 2020
- Oncology in the time of COVID - 15 July 2020
- COVID-19 PANDEMIC: Modelling from the US National Cancer Institute (NCI) predicts the pandemic will result in an excess of over 10,000 deaths from breast and colorectal cancer in the USA, due to missed screening and delayed therapy. - 29 June 2020
- DRUG TARGETS: A novel ATR inhibitor has cleared phase I development with manageable toxicity; responses were seen in tumours harbouring ATM/ARID1A and BRCA1 alteration (colorectal and ovarian respectively) - 29 June 2020
- BLADDER CANCER: In a retrospective analysis, both ARID1A mutation and CXCL13 expression showed positive correlation with response to checkpoint inhibition, including overall survival. Combining the markers improved prediction. - 29 June 2020
- GASTROINTESTINAL CANCER: Promising results from a small phase Ib study of regorafenib + nivolumab in advanced gastric or colorectal cancer: ORR 44% & 36% respectively. - 29 June 2020
- CANCER PREVENTION The American Cancer Society (ACS) have updated their diet and physical exercise guidelines to advise avoidance of all alcohol, a change from previous guidance advising moderation. - 22 June 2020
- BREAST CANCER For newly diagnosed ER+ disease, neoadjuvant anti-oestrogen therapy may be an acceptable bridge to surgery in the face of COVID-19 related delays - 22 June 2020
- RENAL CANCER In a retrospective analysis, rechallenge with immunotherapy delivered ORR 23% (compared with 37% ORR for first exposure); responses at rechallenge were not restricted to those who had responded at first exposure. - 22 June 2020
- LYMPHOMA The FDA have approved the EZH2 inhibitor tazemetostat in folliciular lymphoma, third line for EZH2-mutant disease, or where there are no other treatment options for EZH2 wild-type disease - 22 June 2020
- LUNG CANCER Using genomic analysis to ascertain loss of heterozygosity at the HLA locus in combination with tumour mutational burden (TMB) provided better prediction of response to immunotherapy compared with TMB alone. - 22 June 2020
- IMMUNOTHERAPY The FDA have granted pan-cancer approval for the PD-1 inhibitor pembrolizumab for cancers with tumour mutational burden >10 mut/mb, adult and paediatric. - 22 June 2020
- COVID-19 PANDEMIC Urgent referrals for suspected cancer were down 60% in April in the UK; some cancer types were differentially affected with suspected breast cancer referrals down 78%. - 22 June 2020
- CHOLANGIOCARCINOMA A small single arm study of PD-1 inhibition (nivolumab) for previously treated biliary tract cancers showed ORR 11% - 26 May 2020
- DRUG TARGETS: MET A phase I study of an anti-MET antibody (telisotuzumab) in advanced cancers reported partial responses in MET amplified tumours - 26 May 2020
- DRUG TARGETS: KRAS Disappointing results from ASCO of the KRAS G12C inhibitor (AMG-510), with a study in colorectal cancer and a basket study of non-NSCLC/CRC indications both delivering ORR 12%. - 26 May 2020
- PROSTATE CANCER: A PROTAC-based androgen receptor degrader has shown anti-tumour activity in first in human studies presented at ASCO. - 26 May 2020
- PROSTATE CANCER The FDA have granted accelerated approval to the PARP inhibitor rucaparib for BRCA-mutated (germline or somatic) metastatic castrate-resistant disease. - 26 May 2020
- MELANOMA: In a retrospective study of patients with advanced disease who achieved a complete response to immunotherapy, cessation of therapy was associated with a 27% risk of subsequent disease progression. - 26 May 2020
- HEPATOCELLULAR CANCER Combination PD-L1 and VEGFR inhibition (atezolizumab plus bevacizumab) delivered better overall and progression-free survival than standard of care sorafenib in a pivotal phase 3 study. - 26 May 2020
- LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectively - 11 May 2020
- LUNG CANCER: Data from TRACERx presented at AACR provides further support for the use of personalised ctDNA assays in the assessment of minimal residual disease and impending progression following surgery for early stage disease - 11 May 2020
- GASTRIC/COLORECTAL CANCER: Promising early efficacy data for combined regorafenib plus nivolumab: ORR 44% and 36% for gastric and colorectal respectively, all bar one with microsatellite stable disease - 11 May 2020
- MELANOMA: The addition of PD-L1 blockade (atezolizumab) to combined BRAF/MEK inhibition (vemurafenib + cobimetinib) improved PFS as first line therapy in advanced BRAF V600 mutant melanoma. Survival data are awaited - 11 May 2020
- PANCREATIC CANCER: Addition of a PARP inhibitor (veliparib) to gemcitabine + cisplatin chemo did not improve outcomes for patients harbouring germline mutations in BRCA1/2 or PALB2 - 11 May 2020
- EARLY CANCER DETECTION: Data from GRAIL presented at AACR indicate continued progress in the development of a methylation-based ctDNA assay with high specificity for the early detection of cancer - 11 May 2020
- 47% of cancer overall positive response to treatment thanks to OncoDEEP combined tumour molecular profiling - 11 May 2020
Scientific Review
- Scientific Review: latest discoveries in precision oncology - 27 May 2024
- Scientific Review: Latest Discoveries in Oncology - 3 October 2023
Video
- Discover the new OncoKDM™: enhanced precision for your laboratory - 27 May 2024
- Decoding Cancer: OncoDEEP Kit revolutionises genomic analysis for personalised treatment - 15 November 2023
- Testimonial of OncoDNA’s Journey through its founder’s words - 22 August 2023
- Precision oncology solutions: From molecular profiling to clinical decision with OncoKDM - 13 May 2023
